A New Jersey federal judge on Tuesday blocked Emcure Pharmaceuticals and Teva Pharmaceuticals from proceeding with generic versions of Sunovion Pharmaceuticals’ bipolar disorder drug Latuda after the parties agreed to enter a final judgment that allows the defendants to appeal a key claims construction ruling.
The permanent injunction bars Emcure and Teva from bringing their generics to market until Jan. 2, 2019, when Sunovion’s patent is set to expire. However, the parties are free to appeal to the U.S. Court of Appeals for the Federal Circuit a Nov. 15 ruling on how a claim in the patent was constructed.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
